TRIP6 and ovarian carcinoma: Herein, we aimed to investigate the expression profile of the suspect molecules ABCC3, CPS1, and TRIP6 in ovarian carcinoma cell lines resistant to paclitaxel and reveal potential deregulation of the expression of ABCC3, CPS1 and/or TRIP6 after the treatment with paclitaxel and Stony Brook Taxane derivatives (SB-T-121605 and SB-T-121606) [18] in a model of ovarian carcinoma cells in vitro, and corresponding mouse tumor xenografts in vivo.